We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-1.18%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$509M
AUM Growth
-$864K
Cap. Flow
+$29.1M
Cap. Flow %
5.72%
Top 10 Hldgs %
50.89%
Holding
58
New
16
Increased
12
Reduced
14
Closed
14

Top Buys

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$20.6M
2
CYTK icon
Cytokinetics
CYTK
+$20.4M
3
ANAB icon
AnaptysBio
ANAB
+$19.2M
4
EOLS icon
Evolus
EOLS
+$18.1M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$14.4M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$20.6M
2
VTYX
Ventyx Biosciences
VTYX
+$13.1M
3
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$12.5M
4
PTCT icon
PTC Therapeutics
PTCT
+$11.5M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.46M

Sector Composition

Rank Sector Weight
1 Healthcare 99.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
26
MoonLake Immunotherapeutics
MLTX
$1.57B
$5.95M 1.17%
278,334
-364,232
-57% -$6.12M
GRCL
27
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$5.86M 1.15%
3,153,206
+1,190,807
+61% +$2.49M
CBAY
28
DELISTED
Cymabay Therapeutics
CBAY
$4.43M 0.87%
507,500
-1,042,500
-67% -$8.35M
GBIO
29
DELISTED
Generation Bio
GBIO
$4.4M 0.86%
102,254
– –
ABOS icon
30
Acumen Pharmaceuticals
ABOS
$155M
$4.27M 0.84%
1,051,267
-65,314
-6% -$341K
FOLD
31
DELISTED
Amicus Therapeutics
FOLD
$4.21M 0.83%
+380,000
New +$4.68M
LRMR icon
32
Larimar Therapeutics
LRMR
$397M
$4.08M 0.8%
900,000
-373,635
-29% -$1.95M
ITCI
33
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.81M 0.75%
+70,371
New +$3.4M
ETNB
34
DELISTED
89bio
ETNB
$3.81M 0.75%
+250,000
New +$3.26M
ACRS icon
35
CALL
Aclaris Therapeutics
ACRS
$726M
$2.02M 0.4%
+250,000
New +$3.17M
ZVRA icon
36
Zevra Therapeutics
ZVRA
$562M
$1.91M 0.38%
+347,824
New +$1.84M
DAWN
37
DELISTED
Day One Biopharmaceuticals
DAWN
$1.89M 0.37%
141,526
-402,925
-74% -$7.87M
RYTM icon
38
Rhythm Pharmaceuticals
RYTM
$6.81B
$1.74M 0.34%
+97,544
New +$2.45M
PRAX icon
39
Praxis Precision Medicines
PRAX
$8.58B
$1.64M 0.32%
+135,503
New +$5.72M
VKTX icon
40
PUT
Viking Therapeutics
VKTX
$3.7B
$1.33M 0.26%
+80,000
New +$826K
SLDB icon
41
Solid Biosciences
SLDB
$794M
$997K 0.2%
+210,405
New +$1.26M
AVTX icon
42
Avalo Therapeutics
AVTX
$965M
$831K 0.16%
+1,978
New +$1.56M
OKUR
43
OnKure Therapeutics
OKUR
$154M
$723K 0.14%
+12,086
New +$438K
URGN icon
44
UroGen Pharma
URGN
$1.86B
$362K 0.07%
39,222
-520,778
-93% -$4.79M
ALKS icon
45
Alkermes
ALKS
$8.22B
– –
-46,185
Closed -$1.21M
ERAS icon
46
Erasca
ERAS
$6.3B
– –
-1,538,461
Closed -$6.63M
IMUX icon
47
Immunic
IMUX
$190M
– –
-63,218
Closed -$885K
NVCR icon
48
PUT
NovoCure
NVCR
$1.73B
– –
-241,000
Closed -$17.7M
PTCT icon
49
PTC Therapeutics
PTCT
$5.64B
– –
-302,135
Closed -$11.5M
RCKT icon
50
CALL
Rocket Pharmaceuticals
RCKT
$340M
– –
-451,000
Closed -$8.83M
1
2
3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q1 2023 Portfolio in Review

As of Q1 2023, Great Point Partners held 58 positions worth $509M, down 0.17% from $510M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Great Point Partners deployed $29.1M of net new capital in Q1 2023, opening 16 new positions and adding to 12 existing holdings. Its largest new stake was Cytokinetics: 500,000 shares worth $17.6M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 95% a quarter earlier.

On the sell side, the largest reduction was Cymabay Therapeutics, an estimated $8.35M trimmed.

  • Great Point Partners's largest Q1 2023 buy was Cytokinetics: 500,000 shares worth $17.6M.
  • Great Point Partners added most to Amylyx Pharmaceuticals in Q1 2023, an estimated $20.6M increase.
  • Great Point Partners's biggest Q1 2023 reduction was Cymabay Therapeutics, cutting an estimated $8.35M.
  • Great Point Partners fully exited Seagen Inc. Common Stock in Q1 2023, selling an estimated $20.6M.
  • Great Point Partners's ten largest holdings make up 51% of its $509M portfolio in Q1 2023.
  • Great Point Partners opened 16 new positions and closed 14 in Q1 2023.
  • Great Point Partners's portfolio value fell 0.17% quarter-over-quarter to $509M.

Based on Great Point Partners's 13F filing for Q1 2023, filed 15 May 2023.